Company intelligence / Profile preview
CellMosaic
Woburn, Massachusetts, USA
- Ownership
- Private
- Development stage
- Other
01
Overview
CellMosaic’s ADC technology enabled rapid antibody-drug conjugate validation with anti-metastatic activity in breast and pancreatic cancer models, demonstrating reduction of circulating tumor cells without detectable toxicity. Its technologies are commercial (kits, reagents, contract services), used by leading academic and industry partners; preclinical and research-stage for own therapeutic innovations.
- Therapeutic areas
- OncologyOtherEndocrinologyPsychiatry
- Modalities
- Antibody-drug conjugateAntibodyProteinPeptideSmall moleculeEnzyme replacement therapyGene therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Massachusetts General BrighamStanford UniversityYale UniversityIBEX Biosciences
Beyond the preview
Go deeper on CellMosaic.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CellMosaic.